These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 26317252)

  • 1. Moving beyond the "LDL hypothesis".
    Werner C; Laufs U
    Vasa; 2015 Sep; 44(5):333-40. PubMed ID: 26317252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HDL-C: role as a risk modifier.
    Barter P
    Atheroscler Suppl; 2011 Nov; 12(3):267-70. PubMed ID: 22152280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Models for describing relations among the various statin drugs, low-density lipoprotein cholesterol lowering, pleiotropic effects, and cardiovascular risk.
    Robinson JG
    Am J Cardiol; 2008 Apr; 101(7):1009-15. PubMed ID: 18359323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in prescription patterns before and after reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial (ENHANCE) results and expected effects on low-density lipoprotein-cholesterol reduction.
    Toth PP; Ballantyne CM; Davidson MH; Tomassini JE; Ramey DR; Neff D; Tershakovec AM; Hu XH; Tunceli K
    J Clin Lipidol; 2012; 6(2):180-91. PubMed ID: 22385552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe.
    Daskalopoulou SS; Mikhailidis DP
    Curr Med Res Opin; 2006 Mar; 22(3):511-28. PubMed ID: 16574035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease.
    Toth PP; Foody JM; Tomassini JE; Sajjan SG; Ramey DR; Neff DR; Tershakovec AM; Hu XH; Tunceli K
    J Clin Lipidol; 2014; 8(1):107-16. PubMed ID: 24528691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering.
    Pedersen TR
    Am J Cardiovasc Drugs; 2010; 10 Suppl 1():10-7. PubMed ID: 21391729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statins and LDL-cholesterol lowering: an overview.
    Stroes E
    Curr Med Res Opin; 2005; 21 Suppl 6():S9-16. PubMed ID: 16138936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Altering the pathophysiology of atherosclerosis: the multidimensional role of statins.
    Clearfield MB
    J Am Osteopath Assoc; 2010 Apr; 110(4 Suppl 4):S2-6. PubMed ID: 20453192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin.
    Gazi IF; Daskalopoulou SS; Nair DR; Mikhailidis DP
    Curr Med Res Opin; 2007 Sep; 23(9):2183-92. PubMed ID: 17692154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensive statin therapy for Indians: Part-I. Benefits.
    Enas EA; Pazhoor HC; Kuruvila A; Vijayaraghavan K
    Indian Heart J; 2011; 63(3):211-27. PubMed ID: 22734339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
    Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J
    Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pleiotropic effects of HMG-CoA reductase inhibitors.
    Bocan TM
    Curr Opin Investig Drugs; 2002 Sep; 3(9):1312-7. PubMed ID: 12498006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and effect of very low levels of low-density lipoprotein cholesterol on cardiovascular events.
    LaRosa JC; Pedersen TR; Somaratne R; Wasserman SM
    Am J Cardiol; 2013 Apr; 111(8):1221-9. PubMed ID: 23375731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence supporting primary prevention of cardiovascular diseases with statins: Gaps between updated clinical results and actual practice.
    Bruckert E; Ferrières J
    Arch Cardiovasc Dis; 2014 Mar; 107(3):188-200. PubMed ID: 24613429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of ezetimibe on low-density lipoprotein subtype distribution: results of a placebo-controlled, double-blind trial in patients treated by regular low-density lipoprotein apheresis and statins.
    Geiss HC; Otto C; Parhofer KG
    Metabolism; 2006 May; 55(5):599-604. PubMed ID: 16631435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Statin therapy for atherogenic hypertriglyceridemia].
    Koba S
    Nihon Rinsho; 2013 Sep; 71(9):1655-60. PubMed ID: 24205730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statin and ezetimibe combination therapy in cardiovascular disease.
    Dembowski E; Davidson MH
    Curr Opin Endocrinol Diabetes Obes; 2009 Apr; 16(2):183-8. PubMed ID: 19262375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety.
    Hou R; Goldberg AC
    Endocrinol Metab Clin North Am; 2009 Mar; 38(1):79-97. PubMed ID: 19217513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.